ZYDUSLIFEZydus Lifesciences Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopaedic surgery, including pathologies affecting the hip and knee. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on ZYDUSLIFE — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • ROE: 18.3%
- • Debt/Equity: 0.42
- • Promoter holding: 75.2%
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • Supertrend: bullish
Bull case
- • ROE: 18.3%
- • Debt/Equity: 0.42
- • Promoter holding: 75.2%
- • Price vs SMA200: above
Bear case
- • Profit growth: 8.7% YoY
- • PEG ratio: 2.61
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • Profit growth: 8.7% YoY
- • PEG ratio: 2.61
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹30.66). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.